Precigen (NASDAQ:PGEN) Reaches New 52-Week High After Analyst Upgrade

Precigen, Inc. (NASDAQ:PGEN) shares hit a new 52-week high during mid-day trading on Thursday after Wall Street Zen upgraded the stock from a hold rating to a strong-buy rating. The stock traded as high as $7.23 and last traded at $6.89, with a volume of 16909114 shares traded. The stock had previously closed at $6.53.

Other analysts have also issued reports about the stock. Zacks Research upgraded shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Citizens Jmp lifted their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. Citigroup reiterated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Finally, HC Wainwright lifted their price target on Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Precigen presently has an average rating of “Moderate Buy” and an average price target of $14.50.

Insider Transactions at Precigen

In other news, CFO Harry Jr. Thomasian sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $6.06, for a total transaction of $606,000.00. Following the transaction, the chief financial officer directly owned 254,535 shares in the company, valued at approximately $1,542,482.10. This trade represents a 28.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 32,739 shares of Precigen stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $6.86, for a total transaction of $224,589.54. Following the completion of the transaction, the chief operating officer directly owned 465,012 shares in the company, valued at $3,189,982.32. The trade was a 6.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 989,239 shares of company stock valued at $5,472,960 over the last quarter. Company insiders own 41.40% of the company’s stock.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

Institutional Investors Weigh In On Precigen

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in shares of Precigen during the second quarter worth about $97,737,000. State Street Corp raised its stake in Precigen by 141.1% during the 4th quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock valued at $45,248,000 after acquiring an additional 6,335,033 shares during the last quarter. SymBiosis Capital Partners LLC acquired a new stake in Precigen during the 4th quarter worth approximately $12,540,000. Bank of America Corp DE lifted its position in Precigen by 201.1% during the 3rd quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after acquiring an additional 1,673,731 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Precigen by 196.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company’s stock valued at $9,087,000 after purchasing an additional 1,440,446 shares during the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Stock Up 4.6%

The company has a market capitalization of $2.58 billion, a PE ratio of -6.95 and a beta of 1.02. The company has a current ratio of 4.58, a quick ratio of 4.12 and a debt-to-equity ratio of 2.15. The firm has a 50 day simple moving average of $5.23 and a two-hundred day simple moving average of $4.50.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The firm had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. Precigen’s quarterly revenue was up 6322.7% on a year-over-year basis. Research analysts expect that Precigen, Inc. will post 0.05 EPS for the current year.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.